<DOC>
	<DOCNO>NCT02022124</DOCNO>
	<brief_summary>Patients randomize receive open-label ( honestly describe placebo ) immediately baseline eligible receive open-label treatment three week baseline measurement . Therefore patient eligible receive open-label placebo treatment chronic low back pain course study .</brief_summary>
	<brief_title>Open Label Placebo Treatment Low Back Pain</brief_title>
	<detailed_description>Chronic low back pain ( cLBP ) debilitate costly condition affect 1.2 million Portuguese estimate cost United Stated $ 50 billion . Randomized controlled trial show placebo intervention dramatically reduce chronic low back pain associated disability . Generally , assume response placebo require concealment deception , present dilemma clinician . In clinical practice , patient benefit available , effective potentially cost-effective intervention without deceive ? This study seek determine ethically acceptable open-label placebo treatment ( full inform consent ) lead meaningful benefit . The primary study involve 80 patient cLBP randomly assign three-week course either non-deceptive open-label placebo pill context persuasive rationale + treatment usual continue treatment-as-usual . Primary outcome measure pain intensity symptom bothersomeness previous week . Additionally , study investigate possible association genetic variation catechol-O-methyltransferase ( COMT polymorphisms ) hypothesize observed placebo effect cLBP patient . Participants follow 3 week mid-point ( 11 day ) visit . Patients receive usual care first three week eligible elect three week course treatment open-label placebo assess . This study submit approve follow review board : Comissão de Ética Centro Hospitalar de Lisboa Ocidental ( Lisbon West Hospitals Centre 's Ethical Committee ) Institutional Review Board .</detailed_description>
	<mesh_term>Back Pain</mesh_term>
	<mesh_term>Low Back Pain</mesh_term>
	<criteria>Male female 18 year old Low back pain complaint min . 3 month use strong opioid analgesic and/or anticonvulsant medication ; specific cause back pain namely cancer , fracture infection ; complicate back problem ( e.g . prior back surgery ) ; condition make treatment difficult ( e.g . paralysis , psychosis ) ; condition might confound treatment effect interpretation result ( e.g . severe fibromyalgia , rheumatoid arthritis ) ; concurrent care provider ; condition affect safety patient ( e.g . pregnancy ) ; concurrent medical legal issue .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>chronic low back pain</keyword>
	<keyword>open-label placebo</keyword>
</DOC>